Innovation
Making a difference to human health and patient care
The Faculty’s healthcare research and innovation translates into real impact on patient care and policy. Our researchers and academics work closely with clinical partners, patients, industry and government agencies to ensure that research is mapped against societal need and answers questions that help our hospitals and our governments deliver genuine improvements to health and care.
We use a range of methods to ensure our research outputs make a real difference. Clinical trials, spin- out companies, knowledge transfer partnerships, licences and patents are all used to translate research into useable outputs so that findings get beyond the lab and seminar room into people’s lives.
To make these processes as easy as possible we have developed a gateway for collaboration and innovation management between healthcare researchers, practitioners, policy makers and industry:
The Sheffield Healthcare Gateway puts researchers in touch with industrial and clinical partners, identifies funding and potential investors and acts as a one-stop shop for managing commercial opportunities arising from research.
Sheffield Healthcare Gateway.
See:
http://shg.sheffield.ac.uk
With Fusion IP, the University’s commercialisation partner, spin-out companies and licences produced by the Faculty include:
Asterion Developing long-acting biopharmaceutical products for the treatment of serious and chronic growth hormone disorders.
Zilico Developing a real-time cervical cancer detection device.
SWORD The first and only worldwide evidence-based speech therapy software for the treatment of apraxia of speech following stroke.
Adjuvantix Enhanced vaccine adjuvant system for the treatment of cancer and infectious disease.
Diurnal Creating replacement hormone products that mimic the body’s natural hormone rhythms, used in the treatment of adrenal insufficiency (cortisol deficiency).
Medella Therapeutics Developing new monoclonal antibody drugs that stop cancerous tumours growing and have fewer side effects than currently available therapies.
Faculty Innovation Lead: Professor Richard Ross, MD FRCP
r.j.ross@
sheffield.ac.uk
11
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40